CNS Pharmaceuticals Files to Sell 3.76M Shares of Common Stock for Holders
November 21, 2023
☀️Trending News
CNS ($NASDAQ:CNSP) Pharmaceuticals has filed to offer 3.76 million shares of common stock to shareholders. This offering is an effort for the company to increase capital in order to fund the research and development of novel treatments for brain cancer. CNS Pharmaceuticals is a clinical-stage biotechnology company that focuses on developing targeted therapies for treating highly lethal, central nervous system tumors in adults. The company’s lead product candidate, Berubicin, is a novel anthracycline chemotherapy specifically designed for brain cancer. Proceeds from the offering will be used to fund the development of Berubicin, as well as general corporate purposes.
Stock Price
This news caused the stock to open at $2.6 and close at $2.5, signaling a 7.9% drop from the previous closing price of $2.7. These shares would be made available through a firm that CNS has engaged for the sale. Proceeds from the sale of these shares would go to the selling holders and not to CNS. The company has stated that it will not receive any proceeds from the sale of these shares. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cns Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -17.51 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cns Pharmaceuticals. More…
| Operations | Investing | Financing |
| -12.35 | -0 | 7.67 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cns Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.45 | 4 | 0.59 |
Key Ratios Snapshot
Some of the financial key ratios for Cns Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -367.8% | -169.5% |
Analysis
GoodWhale conducted an analysis of CNS PHARMACEUTICALS‘ wellbeing and assessed the company’s health score on our Star Chart. Our analysis revealed that the company is strong in, and weak in asset, dividend, growth, and profitability. We assigned a health score of 0/10, which means that company is less likely to safely ride out any crisis without the risk of bankruptcy. Furthermore, we classified CNS PHARMACEUTICALS as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. Therefore, it may be of interest to investors who are looking for a long-term investment opportunity that is safe and reliable. These investors should ensure that they have done their due diligence and are comfortable with the company’s performance before investing. More…
Peers
CNS Pharmaceuticals Inc is in a highly competitive market, with multiple other corporations vying for the same customers and resources. Its main competitors are Destiny Pharma PLC, Annovis Bio Inc, and Alk-Abello A/S, all of which have a strong presence in the industry. The competition between these companies is fierce, as each strives to gain an edge over its competitors and become the top choice for customers.
– Destiny Pharma PLC ($LSE:DEST)
Destiny Pharma PLC is a biotechnology company that develops and commercializes novel antimicrobial drugs to address unmet therapeutic needs. As of 2023, Destiny Pharma PLC has a market cap of 28.53M, which indicates its current market value. Additionally, the company has a Return on Equity of -48.88%, which measures how much profit the company has generated relative to shareholder’s investments. This suggests that the company has not been able to generate profits and is failing to achieve its investor’s expectations.
– Annovis Bio Inc ($NYSE:ANVS)
Annovis Bio Inc is a biotechnology company that specializes in developing innovative treatments for neurodegenerative diseases. The company has a market cap of 103.61M as of 2023, indicating that it is a relatively small company with a lower than average market capitalization. Additionally, the company has a Return on Equity (ROE) of -54.71%, suggesting that the company’s investments are not providing a significant return. This could be due to the high cost of developing new treatments for neurodegenerative diseases, and could indicate that the company is facing financial difficulty.
– Alk-Abello A/S ($OTCPK:AKBLF)
Alk-Abello A/S is a global life science company that produces and markets pharmaceutical products, specialty proteins, and diagnostic kits. The company has a market cap of 3.4 billion as of 2023, which reflects its strong financial performance over the past few years. Alk-Abello has achieved a 7.42% return on equity, indicating that the company has been able to generate significant returns on its shareholders’ investments. The company has also been able to significantly increase its revenues and profits over the past few years, which has enabled it to continuously raise its market capitalization.
Summary
CNS Pharmaceuticals has recently filed to sell 3.76 million shares of their common stock to holders, causing the stock price to drop the same day. Analysts recommend that investors proceed with caution when considering an investment in this company. Investors should thoroughly review the financials of the company, including its debt levels, revenue and earnings growth, and any pending developments or news releases.
Additionally, they should compare the stock’s valuation with its peers in the industry, as well as its performance over time and its technical trends. Finally, investors should also consider the risk tolerance and market environment before deciding on an investment in CNS Pharmaceuticals.
Related Posts
Recent Posts
